drugset / Trial / NCT02305602

A Study of VentriGel in Post-MI Patients

NCT02305602 ↗

Phase 1 Completed 15 enrolled Ventrix, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This Phase I, open label, study will investigate the effects of VentriGel injection in patients who have experienced a first, large ST elevation myocardial infarction (STEMI) treated by PCI within the past 3 years and have evidence of left ventricular remodeling.

Timeline

Start
2015-09
Primary completion
2018-09-05
Completion
2019-06

Drugs

EvaluationDrugModalityDoseRoute
Subject VentriGel Other / unclassified — Other